Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?

Sabbioni, Marzio E E; Bernhard, Jürg; Siegrist, Hans-Peter; Schmitz, Shu-Fang Hsu; Gertsch, Monica Castiglione; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph; Swiss Group for Clinical Cancer Research, (SAKK) (2004). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast cancer research and treatment, 87(1), pp. 75-86. Dordrecht: Springer 10.1023/B:BREA.0000041584.53863.a7

[img]
Preview
Text
Sabbioni2004_Article_DoesSubjectiveBurdenOfEarlyBre.pdf - Published Version
Available under License Publisher holds Copyright.

Download (306kB) | Preview

Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (beta2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of beta2-microglobulin and IL-2r at months 3 and 6. The gradient of beta2-microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6 months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg Theodor

ISSN:

0167-6806

Publisher:

Springer

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:24

Last Modified:

02 Mar 2023 23:23

Publisher DOI:

10.1023/B:BREA.0000041584.53863.a7

PubMed ID:

15377853

Web of Science ID:

000223914600009

BORIS DOI:

10.48350/37816

URI:

https://boris.unibe.ch/id/eprint/37816 (FactScience: 211449)

Actions (login required)

Edit item Edit item
Provide Feedback